EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect

Jian Wu iD, Xiaobei Wang, Min Zhang, Parker Mathews, Yubin Kang

Cells · 2023

DOI: 10.3390/cells12151993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Jian Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Lenalidomide, Multiple Myeloma, Retinoid X Receptors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoid X receptor (RXR) heterodimerizes with the PPAR nuclear hormone receptor and regulates its downstream events. We investigated the effects of RXR agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide’s anti-myeloma activity, T cell functions, and the level of glucose and lipids in vivo. Genetic overexpression and CRISPR/Cas9 knockout experiments were conducted in multiple myeloma (MM) cell lines and Jurkat T cell lines to determine the roles of CRBN in RXR-agonist mediated effects. A xenograft mouse model of MM was established to determine the combination effect of LG100754 and lenalidomide. The combination of RXR agonists and lenalidomide demonstrated synergistic activity in increasing CRBN expression and killing myeloma cells. Mechanistically, the RXR agonists reduced the binding of PPARs to the CRBN promoter, thereby relieving the repressor effect of PPARs on CRBN transcription. RXR agonists downregulated the exhaustion markers and increased the activation markers of Jurkat T cells and primary human T cells. Co-administration of LG100754 and lenalidomide showed enhanced anti-tumor activity in vivo. LG100754 retained its glucose- and lipid-lowering effects. RXR agonists demonstrate potential utility in enhancing drug sensitivity and T-cell function in the treatment of myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideMultiple MyelomaRetinoid X ReceptorsAnimalsHumansMiceGlucosePeroxisome Proliferator-Activated ReceptorsT-LymphocytesRetinoidsTetrahydronaphthalenes

Stichwörter der Autor:innen

CpG islandPPARdiabetesdyslipidemiaimmunomodulatory drugsmetabolomicsmethylationsurvivaltreatment response

Substanzen

GlucoseLenalidomidePeroxisome Proliferator-Activated ReceptorsRetinoid X ReceptorsLG 100754RetinoidsTetrahydronaphthalenes

Autor:innen und Institutionen

  • Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

ORCID-Profile: Jian Wu

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • National Cancer Institute

Zitieren

APA

Wu, J., Wang, X., Zhang, M., Mathews, P., & Kang, Y. (2023). RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. Cells. https://doi.org/10.3390/cells12151993

Vancouver

Wu J, Wang X, Zhang M, Mathews P, Kang Y. RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. Cells. 2023. doi:10.3390/cells12151993

BibTeX
@article{Wu2023,
  author = {Wu, Jian and Wang, Xiaobei and Zhang, Min and Mathews, Parker and Kang, Yubin},
  title = {RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12151993}
}
Kostenlos starten →